BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 9108452)

  • 1. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H; Okano H; Chiocca EA; Saeki Y
    Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
    Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
    Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
    Kamiyama H; Zhou G; Roizman B
    Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
    Chambers R; Gillespie GY; Soroceanu L; Andreansky S; Chatterjee S; Chou J; Roizman B; Whitley RJ
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1411-5. PubMed ID: 7877992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
    Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
    Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.
    Mineta T; Rabkin SD; Martuza RL
    Cancer Res; 1994 Aug; 54(15):3963-6. PubMed ID: 8033122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors.
    Advani SJ; Sibley GS; Song PY; Hallahan DE; Kataoka Y; Roizman B; Weichselbaum RR
    Gene Ther; 1998 Feb; 5(2):160-5. PubMed ID: 9578834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
    Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
    J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
    Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
    Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
    Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
    Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
    Okuda T; Kurokawa M; Matsuo K; Honda M; Niimura M; Shiraki K
    J Med Virol; 2004 Jan; 72(1):112-20. PubMed ID: 14635018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.